4.61
Schlusskurs vom Vortag:
$4.71
Offen:
$4.54
24-Stunden-Volumen:
178.14K
Relative Volume:
0.39
Marktkapitalisierung:
$48.32M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-73.52M
KGV:
-6.9848
EPS:
-0.66
Netto-Cashflow:
$-100.45M
1W Leistung:
-1.91%
1M Leistung:
-9.43%
6M Leistung:
-50.96%
1J Leistung:
-67.85%
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Vergleichen Sie DTIL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
DTIL
Precision Biosciences Inc
|
4.61 | 48.32M | 52.29M | -73.52M | -100.45M | -0.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2024-04-30 | Eingeleitet | Guggenheim | Buy |
2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
2020-07-27 | Fortgesetzt | BTIG Research | Buy |
2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
2020-03-05 | Eingeleitet | Stifel | Buy |
2020-02-25 | Eingeleitet | William Blair | Outperform |
2019-08-09 | Eingeleitet | BTIG Research | Buy |
2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
2019-04-22 | Eingeleitet | Barclays | Overweight |
2019-04-22 | Eingeleitet | Goldman | Buy |
2019-04-22 | Eingeleitet | JP Morgan | Overweight |
2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan
Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia
Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India
Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN
Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India
Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer
Precision BioSciences Reports Positive 2024 Financial Results - TipRanks
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq
Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener
Precision BioSciences Inc Q4 Sales Decline - Nasdaq
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire
Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan
Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia
Precision Biosciences CEO sells $5,359 in stock - Investing.com India
Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire
PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq
Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - StockTitan
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $60 target on Precision BioSciences stock - Investing.com
Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus EliminationKey Trial Updates - Stock Titan
Precision Bio rises after gene editing data: BMO upgrades (update) - MSN
Assessing Precision BioSciences: Insights From 4 Financial Analysts - Benzinga
FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States - CRISPR Medicine News
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - 01Net
Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - StockTitan
Precision BioSciences' IND Application For PBGENE-HBV Gets FDA Clearance; Stock Climbs - RTTNews
Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance - MarketScreener
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - BioSpace
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Brown Melinda | Director |
Mar 26 '25 |
Buy |
4.75 |
1,839 |
8,735 |
9,057 |
Germano Geno J | Director |
Mar 25 '25 |
Buy |
5.30 |
3,250 |
17,225 |
11,057 |
Amoroso Michael | President and CEO |
Mar 24 '25 |
Sale |
5.56 |
964 |
5,360 |
109,540 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):